Scandion Oncology A/S and Alligator Bioscience AB present promising preclinical data

Copenhagen, Denmark, June 30, 2021 – Scandion Oncology (Nasdaq Stockholm: SCOL) and Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced promising preclinical data from their ongoing collaboration exploring the anti-tumor effects on drug resistant cancer by combining Scandion Oncology’s drug candidate SCO-101 and Alligator Bioscience’s candidate drug mitazalimab.

The release as fetched from its publisher. scandiononcology.com ↗